Central Pharmaceutical Joint Stock Company No3 (HNX:DP3)
Vietnam
· Delayed Price · Currency is VND 53,500
-3,200 (-5.64%)
At close: Apr 8, 2025
HNX:DP3 Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 417,485 | 409,731 | 485,074 | 381,077 | 395,721 | Upgrade
|
| Revenue Growth (YoY) | 1.89% | -15.53% | 27.29% | -3.70% | -3.82% | Upgrade
|
| Cost of Revenue | 141,432 | 128,228 | 148,536 | 117,447 | 122,006 | Upgrade
|
| Gross Profit | 276,054 | 281,503 | 336,538 | 263,630 | 273,715 | Upgrade
|
| Selling, General & Admin | 139,372 | 144,618 | 208,717 | 151,491 | 140,383 | Upgrade
|
| Operating Expenses | 139,372 | 144,618 | 208,717 | 151,491 | 140,383 | Upgrade
|
| Operating Income | 136,682 | 136,885 | 127,821 | 112,139 | 133,332 | Upgrade
|
| Interest Expense | -161.5 | -1,594 | -6,475 | -449 | -1,969 | Upgrade
|
| Interest & Investment Income | 15,463 | 21,665 | 10,732 | 7,360 | 12,006 | Upgrade
|
| Currency Exchange Gain (Loss) | -133.63 | -15.04 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -97.52 | 60.97 | 4,412 | -839.85 | -409.28 | Upgrade
|
| EBT Excluding Unusual Items | 151,752 | 157,001 | 136,490 | 118,210 | 142,960 | Upgrade
|
| Gain (Loss) on Sale of Assets | 163.2 | 2.28 | - | - | - | Upgrade
|
| Pretax Income | 151,915 | 157,003 | 136,490 | 118,210 | 142,960 | Upgrade
|
| Income Tax Expense | 30,743 | 31,740 | 27,665 | 23,905 | 28,899 | Upgrade
|
| Net Income | 121,172 | 125,263 | 108,824 | 94,305 | 114,061 | Upgrade
|
| Net Income to Common | 121,172 | 125,263 | 108,824 | 94,305 | 114,061 | Upgrade
|
| Net Income Growth | -3.27% | 15.11% | 15.40% | -17.32% | 37.75% | Upgrade
|
| Shares Outstanding (Basic) | 21 | 21 | 23 | 21 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 21 | 23 | 21 | 21 | Upgrade
|
| Shares Change (YoY) | - | -5.00% | 5.27% | -0.00% | -2.18% | Upgrade
|
| EPS (Basic) | 5635.90 | 5826.22 | 4808.40 | 4386.40 | 5305.20 | Upgrade
|
| EPS (Diluted) | 5635.90 | 5826.22 | 4808.40 | 4386.40 | 5305.20 | Upgrade
|
| EPS Growth | -3.27% | 21.17% | 9.62% | -17.32% | 40.81% | Upgrade
|
| Free Cash Flow | 90,452 | 146,699 | 84,126 | 25,862 | 54,119 | Upgrade
|
| Free Cash Flow Per Share | 4207.10 | 6823.21 | 3717.11 | 1202.91 | 2517.18 | Upgrade
|
| Dividend Per Share | - | 3000.000 | - | 2400.000 | - | Upgrade
|
| Gross Margin | 66.12% | 68.70% | 69.38% | 69.18% | 69.17% | Upgrade
|
| Operating Margin | 32.74% | 33.41% | 26.35% | 29.43% | 33.69% | Upgrade
|
| Profit Margin | 29.02% | 30.57% | 22.43% | 24.75% | 28.82% | Upgrade
|
| Free Cash Flow Margin | 21.67% | 35.80% | 17.34% | 6.79% | 13.68% | Upgrade
|
| EBITDA | 149,542 | 150,864 | - | - | - | Upgrade
|
| EBITDA Margin | 35.82% | 36.82% | - | - | - | Upgrade
|
| D&A For EBITDA | 12,861 | 13,980 | - | - | - | Upgrade
|
| EBIT | 136,682 | 136,885 | 127,821 | 112,139 | 133,332 | Upgrade
|
| EBIT Margin | 32.74% | 33.41% | 26.35% | 29.43% | 33.69% | Upgrade
|
| Effective Tax Rate | 20.24% | 20.22% | 20.27% | 20.22% | 20.21% | Upgrade
|
| Revenue as Reported | 417,485 | 409,731 | 485,074 | 381,077 | 395,721 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.